Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.56 USD | +0.65% | -1.31% | +33.58% |
01:29pm | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
05-08 | Revolution Medicines Q1 Net Loss Narrows | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.58% | 6.53B | |
+22.56% | 46.71B | |
+48.83% | 41.8B | |
-1.51% | 41.52B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
-0.14% | 12.14B | |
-0.47% | 12.08B | |
+26.45% | 11.98B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Piper Sandler Starts Revolution Medicines With Overweight Rating, $43 Price Target